American Journal of Kidney Diseases
Volume 40, Issue 3 , Pages 439-446 , September 2002

Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients

Work was performed at Roche Bioscience, Palo Alto, CA, and Acumen, LLC, Burlingame, CA.

Received 30 January 2002 ,Revised 13 May 2002 ,Accepted 13 May 2002.

References 

  1. Ashai NI, Paganini EP, Wilson JM. Intravenous versus subcutaneous dosing of epoetin: A review of the literature. Am J Kidney Dis. 1993;22(suppl 1):S23–S31
  2. Kaufman JS, Reda DJ, Fye CL, et al.  Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med. 1998;339:578–583
  3. Kaufman JS. Subcutaneous erythropoietin therapy: Efficacy and economic implications. Am J Kidney Dis. 1998;32(suppl 4):S127–S151
  4. Boelaert JR, Schurgers ML, Matthys EG, et al.  Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int. 1989;9:95–98
  5. Salmonson T, Danielson BG, Grahnen A, Wikström B. Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. J Intern Med. 1990;228:53–57
  6. Halstenson CE, Macres M, Katz SA, et al.  Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991;50:702–712
  7. Salmonson T. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin. Scand J Urol Nephrol Suppl. 1990;129:S1–S66
  8. Rice L, Alfrey CP, Driscoll T, Whitley CE, Hachey DL, Suki W. Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis. 1999;33:59–62
  9. National Kidney Foundation: DOQI Clinical Practice . Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis. 1997;30(suppl 3):S192–S240
  10. National Kidney Foundation: K/DOQI Clinical Practice . Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 2001;37(suppl 1):S182–S238
  11. Anonymous . Guideline 9. Route of administration of epoetin. Nephrol Dial Transplant. 1999;14(suppl 5):S19–S20
  12. McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis. 2001;37:E36
  13. Besarab A, Erslev AJ. Recombinant erythropoietin. The effect of market places on socialized patient care. ASAIO J. 1993;39:85–86
  14. Lau J, loannidis JP, Schmid CH. Summing up evidence: One answer is not always enough. Lancet. 1998;351:123–127
  15. 2001 Red Book. Montvale, NJ: Medical Economics; 2001;
  16. Normand SL. Meta-analysis: Formulating, evaluating, combining, and reporting. Stat Med. 1999;18:321–359
  17. Albitar S, Meulders Q, Hammoud H, Soutif C, Bouvier J, Pollini J. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant. 1995;10(suppl 6):S40–S43
  18. Balkovetz DF, Frazier C, Sanders PW. Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit. Nephrol Dial Transplant. 1998;13:2979–2980
  19. Besarab A, Flaharty KK, Erslev AJ, et al.  Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405–1416
  20. Bommer J, Samtleben W, Koch KM, Baldamus CA, Grutzmacher P, Scigalla P. Variation of recombinant human erythropoietin application in hemodialysis patients. Contrib Nephrol. 1989;76:149–158
  21. Bommer J, Barth HP, Zeier M, et al.  Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol. 1991;88:136–143
  22. Boran M, Dalva I, Yazicioglu A, Cetin S. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients. Nephron. 1993;63:113–114
  23. Bovy C, Dubois B, Popovic A, Saint-Remy A, Rorive G. Mode of administration of erythropoietin (rHuEpo)—Does it matter?. Nephrol Dial Transplant. 1995;10:1951A–1952A (abstr)
  24. Canaud B, Bennhold I, Delons S, et al.  What is the optimum frequency of administration of r-HuEPO for correcting anemia in hemodialysis patients?. Dial Transplant. 1995;24:306–329
  25. Castro MCM, Abensur H, Centano JR, Romao JJE, Marcondes M, Sabbaga E. Comparison between thrice-weekly intravenous and once-weekly subcutaneous administration of rHuEPO in hemodialysis patients. Dial Transplant. 1994;23:132–143
  26. De Schoenmakere G, Lameire N, Dhondt A, et al.  The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant. 1998;13:1770–1775
  27. Eidemak I, Friedberg MO, Ladefoged SD, Løkkegaard H, Pedersen E, Skielboe M. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Nephrol Dial Transplant. 1992;7:526–529
  28. Granolleras C, Branger G, Deschodt G, Shaldon S, Nonnast-Daniel B, Pollok M. Daily self-administered subcutaneous erythropoietin: Benefits in haemodialysis patients. Contrib Nephrol. 1990;82:49–54
  29. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. Eur J Clin Pharmacol. 1996;50:171–177
  30. Mondal K, Dressler R, Levine SD, Lynn R. Comparison of the erythropoietic effects of subcutaneous and intravenous erythropoietin (EPO) in hemodialysis patients. Am J Kidney Dis. 1992;19:9A; (abstr)
  31. Morsli R, Moriniere P, El Esper N, Boitte F, Woller M, Fournier A. Comparison of s.c. and i.v. rHuEpo in patients on chronic hemodialysis: Comparable correction of anaemia with lower doses because of greater bioavailability. Nephrol Dial Transplant. 1993;8:961A; (abstr)
  32. Muirhead N, Churchill DN, Goldstein M, et al.  Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol. 1992;12:303–310
  33. Paganini EP, Eschbach JW, Lazarus JM, et al.  Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis. 1995;26:331–340
  34. Parker KP, Mitch WE, Stivelman JC, Macon EJ, Bailey JL, Sands JM. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol. 1997;8:288–293
  35. Pelegri A, Roca R, Rodriguez JA, Fort J, Mayo A. Valuation upon the route of administration of rHuEPO in hemodialysis patients (HP). Kidney Int. 1993;44:1430A; (abstr)
  36. Piazza V, Galli F, Villa G, et al.  β-Erythropoietin (EPO) in hemodialysis patients (HD PTS): Comparison of intravenous and subcutaneous dosages. Ren Fail. 1993;15:292A; (abstr)
  37. Schaller R, Sperschneider H, Thieler H, et al.  Differences in intravenous and subcutaneous application of recombinant human erythropoietin: A multicenter trial. Artif Organs. 1994;18:552–558
  38. Steffensen G, Aunsholt NA, Ahlbom G. Comparative crossover study of intravenously and subcutaneously administered recombinant human erythropoietin in hemodialysis patients. Blood Purif. 1992;10:241–247
  39. Taylor JE, Belch JJF, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clin Nephrol. 1994;41:297–302
  40. Vidau P, Peral V, Tome R, Rodriguez C, Herrera J. Intravenous (i.v.) versus subcutaneous (s.c.) administration of erythropoietin (EPO) in hemodialysis (HD) patients. Kidney Int. 1994;46:571A; (abstr)
  41. Virot JS, Janin G, Guillaumie J, et al.  Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient?. Am J Kidney Dis. 1996;28:400–408
  42. Zehnder C, Blumberg A. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: Comparison between intravenous and subcutaneous administration. Nephron. 1991;57:485–486
  43. Jacobs C, Hörl WH, Macdougall IC, et al.  European Best Practice Guidelines 9-13. Anaemia management. Nephrol Dial Transplant. 2000;15(suppl 4):S33–S42
  44. Hynes DM, Stroupe KT, Greer JW, et al.  Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med. 2002;112:169–175
  45. Lui SF, Wong KC, Li PKT, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in hemodialysis patients. Am J Nephrol. 1992;12:55–60
  46. Lago M, Pérez-Garcia R, Garcia de Vinuesa MS, Anaya F, Valderrabano F. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients. Nephron. 1996;72:723–724
  47. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B, et al. The efficacy of once weekly compared to two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial. Nephrol Dial Transplant. 2000;15:2014–2019
  48. Locatelli F, Baldamus CA, Villa G, Martinez F, Martín de Francisco AL, on behalf of the Study Group . Once weekly compared with three-times weekly subcutaneous epoetin β: Results from a randomized multicenter, therapeutic-equivalence study. Am J Kidney Dis. 2002;40:119–125
  49. Granolleras C, Branger B, Shaldon S, et al.  Subcutaneous erythropoietin: A comparison of daily and thrice weekly administration. Contrib Nephrol. 1991;88:144–148
  50. Aljama P, Bommer J, Canaud B, et al.  Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant. 2001;16(suppl 3):S22–S28
  51. Macdougall IC, Gray SJ, Elston O, et al.  Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392–2395
  52. Amgen Inc . Aranesp™ (darbepoetin alfa). Aranesp™ Physician Package Insert. Thousand Oaks: CA, Amgen Inc; 2001;
  53. Macdougall IC:. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001;16(suppl 3):S14–S21

☆ Supported in part by F. Hoffmann-La Roche Ltd, Switzerland.

☆☆ Address reprint requests to John Hornberger, MD, MS, Acumen, LLC, 1415 Rollins Rd, Ste 110, Burlingame, CA 94010. E-mail: jhornberger@acumen-llc.com

★ 0272-6386/02/4003-0001$35.00/0

PII: S0272-6386(02)00066-5

doi: 10.1053/ajkd.2002.34881

American Journal of Kidney Diseases
Volume 40, Issue 3 , Pages 439-446 , September 2002

Article Tools

* Image Usage & Resolution